Acute Myeloid Leukemia (AML) is a diverse disease that is fatal in the majority of patients.
Acute promyelocytic leukemia (APL) however, a subtype of AML accounting for 5% of all cases,
is very curable. APL cells are highly sensitive to the retinoid all-trans-retinoic acid
(ATRA), which effectively differentiates the leukemic clone. Over 80% of APL patients can be
cured with ATRA based therapies. For patients with non-APL AML, ATRA has little effect.
Consequently, 85% of these patients will succumb to their disease despite conventional
approaches. Little is known about mechanisms of resistance to ATRA in non-APL AML. This
knowledge gap limits the use of ATRA in a disease that already has few effective therapies.
The investigators' preliminary data suggest that non-APL AML cells can be re-sensitized to
ATRA when combined with lysine-specific demethylase 1 (LSD 1) inhibitors. The investigators'
publication in Nature Medicine showed that LSD1 inhibition with tranylcypromine (TCP),
unlocked the ATRA-driven therapeutic response in non-APL AML. Notably, treatment with ATRA
and TCP markedly diminished the engraftment of primary human AML cells in murine models,
indicating that the combination may target leukemia-initiating cells (LIC). The
investigators' data identify LSD1 as a therapeutic target and strongly suggest that it may
contribute to ATRA resistance in non-APL AML. The investigators' central hypothesis is that
ATRA combined with TCP will be safe and effective in a clinical population, and that this
approach will suppress LICs and restore myeloid differentiation programs in patients with
non-APL AML. Testing this hypothesis with the phase I clinical trial outlined in this
protocol, will establish a new treatment paradigm in AML and extend the important
anti-cancer effects of ATRA to all AML subtypes.
Inclusion Criteria:
- Confirmed diagnosis of one of the following:
- Relapsed/refractory Acute Myelogenous Leukemia (AML) as defined by the World
Health Organization (WHO) criteria [therapy-related AML and/or secondary AML
from an antecedent hematologic disorder not excluded].
- Relapsed/refractory Myelodysplasic Syndrome (MDS) as defined by the World Health
Organization (WHO) criteria.
- Adult patients 18 years of age or older
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2
- Adequate organ function as defined as:
- Total bilirubin 1. 5 x ULN
- ALT and AST must be ≤ 3 × ULN
- Creatinine 1. 5 x ULN or calculated creatinine clearance > 50ml/min or
- PT and aPTT ≤ 1. 5 × ULN
Patients with total bilirubin, ALT, AST, Creatinine, PT, and aPTT levels outside the
permitted range are eligible if, in the judgment of the Principal Investigator, the levels
are related to the patient's AML or MDS
- Suitable venous access to allow for all study related blood sampling (safety and
research)
- Estimated life expectancy, in the judgment of the Investigator, which will permit
receipt of at least 6 weeks of treatment.
- Able to understand and willing to signed the written informed consent and HIPAA
document/s.
Exclusion Criteria:
- Therapy with moderate or strong CYP3A4 inhibitors or CYP3A4 inducers within 14 days
prior to Cycle1 Day1.
- Therapy with Monoamine Oxidase Inhibitors (MAOIs), dibenzazepine derivatives,
sympathomimetics, or Selective Serotonin Reuptake Inhibitors (SSRIs) within 14 days
prior to Cycle1 Day1. (Patients actively receiving a safe substitute in the judgment
of the Principal Investigator are eligible and may continue to receive the safe
substitute during protocol treatment)
- Therapy with any investigational products, antineoplastic therapy, or radiotherapy
within 14 days prior to Cycle1 Day1. Patients actively receiving hydroxyurea are
eligible and may continue to receive hydroxyurea during protocol treatment.
- Candidates for standard and/or potentially curative treatments. (Candidate defined as
a patient that is both eligible and willing)
- Major surgery within 28 days prior to Cycle1 Day1.
- Grade 2 or higher diarrhea as defined by NCI CTCAE Version 4. 03 despite optimal
antidiarrheal supportive care within 7 days prior to Cycle1, Day1.
- Myocardial infarction within 6 months (24 weeks) prior to Cycle1, Day1.
- Class III or IV heart failure as defined by the New York Heart Association (NYHA),
uncontrolled angina, severe uncontrolled ventricular arrhythmias, or
electrocardiographic evidence of acute ischemia or active conduction system
abnormalities. (Any ECG abnormality at screening has to be documented by the
investigator as not medically relevant and confirmed by the Principal Investigator)
- Active and uncontrolled infection.
- Known human immunodeficiency virus (HIV) positive.
- Known hepatitis B surface antigen-positive
- Known or suspected active hepatitis C infections (Patients who are hepatitis C
surface antigen-positive are eligible)
- Female patients who are pregnant women or breast feeding. Confirmation that the
patient is not pregnant will require a negative serum β-human chorionic gonadotropin
(β-hCG) pregnancy test result obtained during screening; pregnancy testing is not
required for post-menopausal or surgically sterilized women.
- Females of child bearing potential who refused to either practice 2 effective methods
of contraception at the same time or abstain from heterosexual intercourse from the
time of signing the informed consent through 30 days after the last dose of study
drug
- Males of child bearing potential who refuse to practice effective barrier
contraception during the entire study treatment period and through 4 months after the
last dose of study drug (includes males surgically sterilized - i. e. status post
vasectomy)
- Serious medical or psychiatric illness/condition likely in the judgment of the
Investigator to interfere with compliance to protocol treatment/research.
- Known history of allergic reaction to TCP or ATRA
- Symptomatic CNS involvement
- A concurrent second active and non-stable malignancy (Patients with a concurrent
second active but stable malignancy are eligible)
